Compare KXIN & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KXIN | ACXP |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | China | United States |
| Employees | 13 | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 6.9M |
| IPO Year | N/A | 2021 |
| Metric | KXIN | ACXP |
|---|---|---|
| Price | $5.30 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $95.50 |
| AVG Volume (30 Days) | 60.1K | ★ 89.7K |
| Earning Date | 11-26-2019 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $0.29 |
| 52 Week High | $22.00 | $8.34 |
| Indicator | KXIN | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 54.77 | 39.45 |
| Support Level | $5.30 | $1.36 |
| Resistance Level | $6.09 | $1.75 |
| Average True Range (ATR) | 0.60 | 0.13 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 64.21 | 11.11 |
Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.